These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17311548)

  • 41. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolutionary emergence of angiogenesis in avascular tumors using a spatial public goods game.
    Salimi Sartakhti J; Manshaei MH; Basanta D; Sadeghi M
    PLoS One; 2017; 12(4):e0175063. PubMed ID: 28399181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
    Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis.
    Schättler H; Ledzewicz U; Cardwell B
    Math Biosci Eng; 2011 Apr; 8(2):355-69. PubMed ID: 21631134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A new family of angiogenic factors.
    Martínez A
    Cancer Lett; 2006 May; 236(2):157-63. PubMed ID: 15927357
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis.
    Bauer AL; Jackson TL; Jiang Y
    Biophys J; 2007 May; 92(9):3105-21. PubMed ID: 17277180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
    Osada H; Kakeya H
    Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.
    Cao Y; Zhong W; Sun Y
    Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The ubiquitin-proteasome system meets angiogenesis.
    Rahimi N
    Mol Cancer Ther; 2012 Mar; 11(3):538-48. PubMed ID: 22357635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Discovery of Tumor Angiogenesis Factors: A Historical Overview.
    Ribatti D
    Methods Mol Biol; 2016; 1464():1-12. PubMed ID: 27858351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system.
    Qu B; Guo L; Ma J; Lv Y
    Med Hypotheses; 2010 Feb; 74(2):360-1. PubMed ID: 19744799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimization of vascular-targeting drugs in a computational model of tumor growth.
    Gevertz J
    Phys Rev E Stat Nonlin Soft Matter Phys; 2012 Apr; 85(4 Pt 1):041914. PubMed ID: 22680505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis.
    Drevs J; Schneider V
    J Intern Med; 2006 Dec; 260(6):517-29. PubMed ID: 17116002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic application of anti-angiogenic nanomaterials in cancers.
    Mukherjee S; Patra CR
    Nanoscale; 2016 Jul; 8(25):12444-70. PubMed ID: 27067119
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic inhibition of angiogenesis.
    Zhang HT; Bicknell R
    Mol Biotechnol; 2003 Oct; 25(2):185-200. PubMed ID: 14526126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Anti-angiogenic drugs probable complement in cancer therapy].
    Christofferson R; Claesson-Welsh L; Muhr C
    Lakartidningen; 2002 Oct; 99(42):4138-9, 4142-8. PubMed ID: 12448292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y; Liu Q
    Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microtubule-targeting agents in angiogenesis: where do we stand?
    Pasquier E; Honoré S; Braguer D
    Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Type IV collagen-derived angiogenesis inhibitors.
    Mundel TM; Kalluri R
    Microvasc Res; 2007; 74(2-3):85-9. PubMed ID: 17602710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.